The Patient’s Guide to Spravato and Esketamine Treatment
When the FDA approved esketamine nasal spray for treatment-resistant depression in 2019, it marked a turning point in psychiatric pharmacology. For the first time in decades, a genuinely new class of antidepressant had received regulatory approval, and it worked faster and through a different mechanism than anything that had come before. Five years on, Spravato